{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T22:24:07Z","timestamp":1782080647767,"version":"3.54.5"},"reference-count":33,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>High\u2010dose methotrexate (HDMTX) use can be limited by the development of acute kidney injury (AKI). Early AKI detection is paramount to prevent further renal injury and irreversible toxicities. This study sought to determine whether early elimination patterns of MTX would be useful as a biomarker of AKI in HDMTX treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study included two sites that collected \u22652 MTX levels within 16\u2009h from completion of MTX infusion. Early levels were tagged and MTX elimination half\u2010life (t<jats:sub>\u00bd<\/jats:sub>) were calculated from combinations of two of three different early time periods. Receiver operating characteristic (ROC) curves were synthesized for each elimination t<jats:sub>\u00bd<\/jats:sub> (biomarker) with respect to AKI and delayed methotrexate elimination (DME); the biomarker with the highest area under the ROC curve (AUC) was tested in a multiple variable logistic regression model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from 169 patients who received a total of 556 courses of HDMTX were analyzed. ROC analysis revealed MTX elimination t<jats:sub>\u00bd<\/jats:sub> calculated from the second and third time periods had the highest AUC for AKI at 0.62 (interquartile range [IQR] 0.56\u20130.69) and DME at 0.86 (IQR 0.73\u20131.00). After adjusting for age, sex, dose (mg\/m<jats:sup>2<\/jats:sup>), infusion duration, HDMTX course, and baseline estimated glomerular filtration rate, it remained significant for AKI with an OR of 1.29 and 95% confidence interval of 1.03\u20131.65.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Early MTX elimination t<jats:sub>\u00bd<\/jats:sub> measured within 16\u2009h of infusion completion was significantly associated with the development of AKI and serves as an early clearance biomarker that may identify patients who benefit from increased hydration, augmented leucovorin rescue, and glucarpidase administration.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.70176","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T10:47:06Z","timestamp":1725965226000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Early therapeutic drug monitoring of methotrexate and its association with acute kidney injury: A retrospective cohort study"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9402-5086","authenticated-orcid":false,"given":"Nicol\u00e1s","family":"Tentoni","sequence":"first","affiliation":[{"name":"Laboratory of Applied Statistics in the Health Sciences, School of Medicine University of Buenos Aires  Buenos Aires Argentina"},{"name":"Resonance  Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-4352","authenticated-orcid":false,"given":"Miriam","family":"Hwang","sequence":"additional","affiliation":[{"name":"Resonance  Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6159-1882","authenticated-orcid":false,"given":"Gabriela","family":"Villanueva","sequence":"additional","affiliation":[{"name":"Resonance  Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Combs","sequence":"additional","affiliation":[{"name":"Resonance  Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lowe","sequence":"additional","affiliation":[{"name":"Resonance  Memphis Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6417-3961","authenticated-orcid":false,"given":"Laura B.","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Toxicology &amp; Therapeutic Innovation Children's Mercy Hospital  Kansas City Missouri USA"},{"name":"Department of Pediatrics University of Missouri \u2013 Kansas City School of Medicine  Kansas City Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-2397","authenticated-orcid":false,"given":"Zachary L.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Division of Translational and Clinical Pharmacology Cincinnati Children's Hospital Medical Center  Cincinnati Ohio USA"},{"name":"Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center  Cincinnati Ohio USA"},{"name":"Department of Pediatrics University of Cincinnati College of Medicine  Cincinnati Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8659-1603","authenticated-orcid":false,"given":"Thais Murciano","family":"Carrillo","sequence":"additional","affiliation":[{"name":"Pediatric Oncology and Hematology Service Vall d'Hebron University Hospital  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7584-924X","authenticated-orcid":false,"given":"Mar\u00eda Dolores","family":"Aumente","sequence":"additional","affiliation":[{"name":"Pharmacy Service Reina Sof\u00eda University Hospital\/Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (IMIBIC)\/University of C\u00f3rdoba  C\u00f3rdoba Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3493-6969","authenticated-orcid":false,"given":"Teresa","family":"L\u00f3pez\u2010Vi\u00f1au\u00a0L\u00f3pez","sequence":"additional","affiliation":[{"name":"Pharmacy Service Reina Sof\u00eda University Hospital\/Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (IMIBIC)\/University of C\u00f3rdoba  C\u00f3rdoba Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4828-3893","authenticated-orcid":false,"given":"Carmelo","family":"Rizzari","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Hematology Oncology Unit University of Milano\u2010Bicocca, IRCCS San Gerardo dei Tintori  Monza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2244-1686","authenticated-orcid":false,"given":"Scott C.","family":"Howard","sequence":"additional","affiliation":[{"name":"Resonance  Memphis Tennessee USA"},{"name":"Sant Joan de D\u00e9u Hospital Barcelona  Barcelona Spain"},{"name":"Yeolyan National Hematology Center  Yerevan Armenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0164"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-6-694"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04248-8"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4540"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000486823"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06106-y"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0552-1"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07765.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002729"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13125"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25137"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03980-6"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0243"},{"key":"e_1_2_10_15_1","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Acute Lymphoblastic Leukemia Version 1.2024.nccn.org. Accessed October 6 2023."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1957"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25305"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00182"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2023.1193494"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc5713"},{"key":"e_1_2_10_21_1","unstructured":"VORAXASE.(Glucarpidase) highlights of prescribing information. FDA.2012Accessed Feb 15 2023https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125327s064lbl.pdf"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.02.337"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008030287"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1088\/1361-6560\/aab4b1"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-2998(78)80014-2"},{"key":"e_1_2_10_26_1","volume-title":"Causal Inferance: What If","author":"Hernan MA","year":"2020"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9781139025751"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-5573-6-4"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.12.2017"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2145"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198602203140803"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.10.029"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20152"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13791"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T09:23:24Z","timestamp":1738920204000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":33,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1002\/cam4.70176"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70176","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"2024-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70176"}}